Trials / Completed
CompletedNCT03526926
A Post-Marketing Observational Study of VYXEOS™
A Post-Marketing Observational Study of VYXEOS™ to Assess the Incidence of Infusion-Related Reactions in Adult Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPX-351 | VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes. |
Timeline
- Start date
- 2018-10-23
- Primary completion
- 2019-10-26
- Completion
- 2020-06-12
- First posted
- 2018-05-16
- Last updated
- 2020-08-05
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03526926. Inclusion in this directory is not an endorsement.